Development of a 3D MRI microvascular mapping tool for breast surgical planning
Author Block: L. Ramos1, H. I. d. S. Guerreiro2, M. G. C. V. Cartucho3, D. A. P. D. A. P. Silva2, C. N. M. d. Santos2; 1Lagoa/PT, 2Faro/PT, 3Portimão/PT
Purpose: To develop and validate a 3D non-contrast breast MRI protocol (1.5T) for breast vascularization preoperative mapping establishing acquisition parameters, image quality criteria, and clinical reproducibility.
Methods or Background: Preoperative characterization of breast vascularization is crucial to preserve the viability of the skin flap and the nipple-areolar complex (NAC), preventing complications such as ischemia or necrosis.
The protocol was developed using a Philips Ingenia 1.5T Omega HP scanner, involving 10 female volunteers selected by strict inclusion and exclusion criteria. TOF and REACT sequences were employed, optimized to maximize acquisition time, vessel-to-tissue contrast, vascular border sharpness, fat suppression, and minimize artifacts, allowing precise characterization of the number of perforators, minimum detectable diameter, subcutaneous path, continuity to the NAC, distance to the NAC, anastomoses, and relevant anatomical variants.
Results or Findings: The optimized 3D non-contrast acquisitions enabled clear visualization of the internal mammary artery, measuring 2.6 mm in diameter, and perforator branches as small as 0.8 mm—a relevant finding since vessels <1.0 mm are usually described only in contrast-enhanced MRI. A continuous vascular path to the NAC was observed in both breasts analyzed.
Conclusion: The 3D non-contrast MRI technique proved effective in identifying clinically relevant vascular structures, enabling delimitation of areas of higher vascularization to preserve, planning incisions to avoid dominant vessels, and personalized ischemia risk assessment of the NAC. Future plans include integrating vascular maps into mixed reality platforms (e.g., Microsoft HoloLens) for preoperative marking/planning and intraoperative support, after validation with a larger sample.
Limitations: Small, healthy sample; single center; sequences still being optimized; not a diagnostic study nor a screening replacement.
Funding for this study: No funding.
Has your study been approved by an ethics committee? Yes
Ethics committee - additional information: Algarve Biomedical Center Ethics Committee approval.